Cancer Research · 2010 · 329 citations · 21 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionOncogene MutationsOncogenic Signaling PathwaysTherapeutic ResistanceTyrosine Kinase InhibitorsAlk InhibitionAlk Point MutationsAnaplastic Lymphoma Kinase InhibitionKinase Inhibitor ResistanceKinase Mutation-mediated ResistanceMolecular Drug ResistanceMutationMyofibroblastic Tumors
The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy. When present in cis with an ALK translocation, this mutation (also detected in neuroblastomas) causes an increase in ALK phosphorylation, cell growth, and downstream signaling. Furthermore, the F1174L mutation inhibits crizotinib-mediated downregulation of ALK signaling and blocks apoptosis in RANBP2-ALK Ba/F3 cells. A chemically distinct ALK inhibitor, TAE684, and the HSP90 inhibitor 17-AAG are both effective in models harboring the F1174L ALK mutation. Our findings highlight the importance of studying drug resistance mechanisms in order to develop effective clinical treatments for patients with ALK-translocated cancers.
21
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou, Dalia Ercan, Liang Chen et al. · Nature · 2009 · 996 citations · Full text
Medicine, Oncology, Pharmacology +12
<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text
Medicine, Oncology, Pharmacology +17
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen, Junko Takita, Young Lim Choi et al. · Nature · 2008 · 914 citations